LXEO · Lexeo Therapeutics, Inc.
$4.55
-0.14 (-2.99%)
At close · Jul 20
Market Cap
$357.27M
Shares
78.52M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$654K
FY2023
Net Income
-$99.96M
-1.7%
FY2025
Operating Margin
-10475.99%
FY2023
Diluted EPS
-$1.86
+39.8%
FY2025
Operating Cash Flow
-$98.56M
-21.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| — | — | — | $654K | |
| $62.33M | $63.8M | $74.09M | $53.13M | |
| $35.46M | $45.46M | $31.68M | $15.38M | |
| — | $268K | $304K | $271K | |
| $97.79M | $109.26M | $105.77M | $68.51M | |
| -$97.79M | -$109.26M | -$105.77M | -$68.51M | |
| — | — | — | -10475.99% | |
| — | -$108.99M | -$105.46M | -$68.24M | |
| $84K | $95K | $137K | $205K | |
| $7.05M | $6.13M | $7.56M | $2.87M | |
| $10.28M | $9.3M | $7.43M | $2.12M | |
| -$87.21M | -$99.67M | -$98.33M | -$66.39M | |
| — | $0 | — | — | |
| -$87.54M | -$99.96M | -$98.33M | -$66.39M | |
| — | — | — | -10151.99% | |
| -$87.59M | -$99.67M | -$98.44M | — | |
| USD/shares | — | -$1.86 | -$3.09 | -$12.40 |
| USD/shares | — | -$1.86 | -$3.09 | -$12.40 |
| shares | — | 53.65M | 31.79M | 5.35M |
| shares | — | 53.65M | 31.79M | 5.35M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.46×
EV/EBIT
—
Biotechnology median 26.20×
P/E (TTM)
—
Biotechnology median 7.03×
Valuation over time computed as of each quarter's filing date
Key facts
CIK
1907108
CUSIP
52886X107
13F (30d)
11 filings
10 filers
Visit website
Investor relations